

1 **Title Page**

2 **Vitamin D deficiency and toxicity across 2018 to 2022 in several cities of**
3 **Ecuador: interrupted time series and a cross-sectional study**

4 **Short Title:** Vitamin D deficiency and toxicity across 2018 to 2022 in several cities
5 of Ecuador

6 **Authors:**

7 Camilo Zurita-Salinas^{a,b} , Betzabé Tello^{c,d} , Iván Dueñas-Espín^e , Jeannete
8 Zurita^{a,c}, William Acosta^c , Cristina Aguilera León^a, Andrés Andrade-Muñoz^c , José
9 Pareja-Maldonado^c.

10 ^a Biomedical Research Unit. Zurita & Zurita Laboratories, Quito, Ecuador.

11 ^b Facultad de Ciencias Médicas. Universidad Central del Ecuador, Quito, Ecuador.

12 ^c Facultad de Medicina. Pontificia Universidad Católica del Ecuador, Quito,
13 Ecuador.

14 ^d Centro de Investigación para la Salud en América Latina CISEAL, Quito,
15 Ecuador.

16 ^e Instituto de Salud Pública. Pontificia Universidad Católica del Ecuador, Quito,
17 Ecuador.

18 *** Corresponding author**

19 Betzabé Tello, Centro de Investigación para la Salud en América Latina CISEAL,
20 Facultad de Medicina. Pontificia Universidad Católica del Ecuador, Quito, Ecuador,
21 Av. 12 de octubre 1076 and Roca, postal code: 170525, phone number: (593) (02)
22 2991700 Ext 2881, Quito – Ecuador; e-mail: bmtello@puce.edu.ec

23

24 **Abstract**

25 **Objectives:** to identify differences in mean vitamin D concentrations in samples
26 obtained from a private laboratory in the city of Quito, and to explore their
27 relationship with the pre-pandemic and pandemic periods spanning from 2018 to
28 2022.

29 **Design:** A combination of an interrupted time series design and a retrospective
30 cross-sectional approach

31 **Setting and participants:** The study involved 9,285 participants who had their 25-
32 hydroxyvitamin D (25(OH)D) levels tested at a well-known private laboratory in
33 Quito, Ecuador, from 2018 to 2022.

34 **Primary and secondary outcome measures:** The 25(OH)D levels were analyzed
35 and assessed for correlations with both age and the year in which the
36 measurements were taken.

37 **Results:** The mean 25-hydroxyvitamin D (25(OH)D) level was 27.53 ng/mL (\pm
38 14.11). Approximately 64.58% of participants had insufficient levels, below 20
39 ng/mL, and 0.62% showed potential harm from excess 25(OH)D, with levels over
40 100 ng/mL. The analysis indicated a significant monthly increase of 0.133 units in
41 25(OH)D levels ($p=0.006$). However, the period after March 2020, compared to
42 before, saw a non-significant decrease of 1.605 units in mean 25(OH)D levels
43 ($p=0.477$).

44 **Conclusions:** The study's findings indicate a significant prevalence of 25-
45 hydroxyvitamin D (25(OH)D) deficiency, underscoring the necessity for
46 preventative measures. Nevertheless, the rise in cases of vitamin D toxicity is
47 concerning, emphasizing the importance of prudent vitamin D supplement
48 prescriptions and public education against self-medication. For efficient resource
49 allocation and targeting those with higher risks, it may be advantageous to
50 concentrate vitamin D testing on specific population groups.

51

52 **Keywords:** 25-hydroxyvitamin-D; vitamin D deficiency; vitamin d toxicity,
53 hypervitaminosis d, overdose.

54 **Introduction**

55 Vitamin D, a prohormone, has a crucial influence on a multitude of biological
56 processes, encompassing immunological responses, phosphocalcic metabolism,
57 and detoxification. Recent revelations regarding the diverse functions of vitamin D
58 have engendered escalating interest among the scientific community, fostering an
59 ongoing commitment to further research in this realm. The intricate regulation of
60 vitamin D is governed by a complex interplay of genetic and environmental factors,
61 underscoring the multifaceted nature of its mechanisms [1].

62 The primary source of vitamin D in humans stems from the interaction of UVB
63 radiation with the skin during sunlight exposure. When the skin is exposed to
64 ultraviolet radiation, a photochemical reaction occurs; cleaving carbon bonds in the
65 precursor of vitamin D, 7-dehydrocholesterol, to form pre-vitamin D₂. Subsequent
66 temperature-dependent molecular rearrangements facilitate the production of
67 active vitamin D, which can be stored within the body for several months due to its
68 liposoluble nature[2]. In addition to sunlight, vitamin D can also be obtained from
69 external sources such as certain foods and supplements[1].

70 Defining the optimal level of 25(OH)D, the major circulating form of vitamin D,
71 remains a topic of ongoing debate[3]. Some studies have highlighted a potential
72 overestimation of vitamin D deficiency prevalence in the population, fueling
73 controversy over the necessity of supplementation in healthy individuals[3].
74 Notably, The Endocrine Society defines deficiency as <20 ng/ml, insufficiency as
75 21-29 ng/ml, and optimal levels as >30 ng/ml, while the Institute of Medicine
76 (Health and Medicine Division of the National Academies) considers deficiency as
77 <12 ng/ml, insufficiency as 12-20 ng/ml, and optimal levels as >20 ng/ml.
78 Furthermore, The American Association of Clinical Endocrinologists defines
79 deficiency as < 30 ng/ml and optimal levels as 30-50 ng/ml[4]. Globally, an
80 estimated 15.7% of the population suffers from a vitamin D deficit, with South
81 America exhibiting a higher prevalence of 34.75%[4,5]. No previous studies in
82 Ecuador have considered altitude and the pandemic. Quito, Ecuador's capital, sits
83 at 2850 meters above sea level.

84 During the COVID-19 pandemic, several studies have documented significant
85 lifestyle changes among individuals, including modifications in dietary patterns,
86 reduced participation in outdoor activities, and a decline in physical exercise[6].
87 These lifestyle shifts have the potential to impact vitamin D synthesis, as they may
88 serve as contributing factors[6,7].

89 Vitamin D deficiency has been linked to acute and chronic diseases that affect not
90 only the skeletal system but also other physiological systems. Timely treatment for
91 individuals with vitamin D deficiency can potentially improve their quality of life and
92 reduce associated health risks[8].

93 The objective of this study was to identify differences in mean vitamin D
94 concentrations in samples obtained from a private laboratory in the city of Quito,
95 and to explore their relationship with the pre-pandemic and pandemic periods
96 spanning from 2018 to 2022.

97 **Methods**

98 *Design*

99 A combination of an interrupted time series design and a retrospective cross-
100 sectional approach was employed in this study to assess shifts in population-level
101 25-hydroxyvitamin D (25(OH)D) status and associated toxicity in Ecuador, pre -
102 and post-onset of the COVID-19 pandemic. Data were collated at multiple time
103 points through cross-sectional measures of previously collected data prior to and
104 following the pandemic's onset. This design facilitated the appraisal of long-term
105 trends and the potential influence of the pandemic on 25-hydroxyvitamin D
106 (25(OH)D) levels and associated toxicity.

107 *Settings*

108 This study was conducted primarily in a large private laboratory in Quito, Ecuador.
109 A diverse cohort of patients was included, most of whom had their 25-
110 hydroxyvitamin D (25(OH)D) levels tested at the request of their physicians. These
111 people came from various cities, primarily from Quito, Ibarra, Ambato, and Santo

112 Domingo. Data from 2018 to 2022 were analyzed, with the exception that for the
113 year 2022 only data from January were included.

114 *Study population and sample size*

115 The study population comprised people who had their 25-hydroxyvitamin D
116 (25(OH)D) levels tested at a large private laboratory in Quito, Ecuador, between
117 the years 2018 and 2022. A vast majority of these tests were performed at the
118 request of the patients' physicians. Patients from various cities such as Quito,
119 Ambato, Ibarra, and Santo Domingo contributed to the diversity of the sample. The
120 total sample size was 9,285. By the year 2022, the sample included only those
121 people whose vitamin D levels were tested in January. Additionally, we performed
122 a secondary analysis in a subsample of 919 patients in which we collected
123 information about chronic diseases and medications in order to calculate the
124 prevalence of inadequate levels of vitamin D in people with and without chronic
125 diseases.

126 *Data collection procedures*

127 There is a consensus among experts regarding the use of serum/plasma 25(OH)D
128 concentration as the preferred method to evaluate vitamin D status. It is widely
129 agreed that this measurement reflects the combined contributions of diet and
130 dermal synthesis. The choice of 25(OH)D is justified by its advantageous
131 characteristics, including its extended half-life of 15 days, relative stability,
132 abundant presence in the blood, and responsiveness to recent endogenous
133 vitamin D production and exogenous intake from diet or supplements[1,9]. The
134 determination of 25-hydroxyvitamin D Total in human plasma was assessed using
135 the ELFA (Enzyme Linked Fluorescent Assay) technique. The measurements were
136 performed using the VIDAS laboratory machine, employing reagents manufactured
137 by Biomerieux. Following the completion of the assay, the results were
138 automatically analyzed by the computer.

139 The instrument automatically calculated the results using stored calibration curves
140 based on a 4-parameter logistics model. The results were expressed in either
141 ng/mL or nmol/L.

142 The VIDAS 25 OH Vitamin D TOTAL measurement range spanned from 8.1 ng/mL
143 to 126.0 ng/mL. Results below the lower limit of the measurement range were
144 reported as "< 8.1 ng/mL," while values above the upper limit were reported as ">
145 126.0 ng/mL.". In this study, the reference value of < 20ng/mL was adopted to
146 classify laboratory samples as "inadequate levels", encompassing values indicating
147 deficiency and insufficiency. Furthermore, values exceeding 100 ng/mL were
148 considered "suggestive toxicity".

149 *Variables*

150 The main variables of interest in this study were serum concentrations of
151 25-hydroxyvitamin D [25(OH)D], age, and the year of measurement. Vitamin D
152 levels were classified as 'deficiency', 'insufficient' and 'sufficient' based on
153 recognized clinical thresholds. We further classified "Suggestive toxicity" when the
154 values were >100 ng/mL, and "Inadequate levels" when the values were deficient
155 or insufficient. Age was stratified into four categories: 'Children and adolescents',
156 'Young adults', 'Middle-aged adults' and 'Older adults'. The year of measurement
157 was used to compare vitamin D levels before and after the start of the COVID-19
158 pandemic. We also considered two outcome variables: 'Suggestive toxicity' and
159 'Inadequate levels'.

160 *Statistical analysis*

161 Descriptive statistics were first calculated to summarize the basic characteristics of
162 the data set, including means and standard deviations for continuous variables,
163 and frequencies and percentages for categorical variables. We stratified the
164 analyzes by age group and by year of measurement to assess temporal trends in
165 25-hydroxyvitamin D (25(OH)D) levels. Chi-square tests were used to examine
166 differences in the distribution of categorical variables between different groups. For
167 continuous variables, independent samples t tests or Mann-Whitney U tests were

168 used, as appropriate. A p-value of less than 0.05 was considered statistically
169 significant. To further explore the relationships between age, year of measurement,
170 and 25-hydroxyvitamin D (25(OH)D) levels, cross-tabulations were performed.
171 These analyzes were used to identify the prevalence of 25-hydroxyvitamin D
172 (25(OH)D) deficiency, insufficiency, sufficiency, suggestive toxicity, and inadequate
173 levels within each age group and year. Results are reported as mean \pm standard
174 deviation (SD) for continuous variables and number (percent) for categorical
175 variables, unless otherwise stated.

176 Two secondary analyses were performed: First, within a subsample of participants
177 to investigate possible selection bias in the study results. The association between
178 self-reported illnesses and inadequate 25-hydroxyvitamin D (25(OH)D) levels was
179 assessed using a chi-square test. Medical conditions were self-reported using the
180 personal data form, and this information was integrated into the laboratory's
181 database, along with data on medication use and comorbidities. Second, a
182 secondary analysis was performed to compare 25-hydroxyvitamin D (25(OH)D)
183 levels between cities located at different altitudes: Quito, Ambato, and Ibarra,
184 located above 2,500 masl, and Santo Domingo, located below 625 masl. The chi-
185 square test was used to examine the association between city location and
186 inadequate vitamin D levels.

187 To examine the potential change in average 25-hydroxyvitamin D (25(OH)D)
188 concentration before and after March 2020 (pre-pandemic and pandemic periods),
189 a multiple linear regression analysis was employed. The independent variables in
190 the analysis included the passage of time (measured in months), a binary variable
191 indicating the period after March 2020, and an interaction term combining these
192 two variables. The dependent variable was the average monthly 25-hydroxyvitamin
193 D (25(OH)D) concentration. The total sample size for the regression analysis was
194 49.

195 For the statistical analysis, a Poisson regression model was utilized to determine
196 the prevalence ratios for two health outcomes, namely toxicity and inadequate
197 levels of 25-hydroxyvitamin D (25(OH)D), over a four-year period (2018-2021). For

198 each outcome, the year of observation was included as a categorical independent
199 variable, and prevalence ratios were estimated in relation to the base year of 2018.
200 Observations from the year 2022 were excluded from the analysis.

201 All statistical analyzes were performed using Stata 15.1 (Stata Corp. 2015. Stata
202 Statistical Software: Release 14. College Station, TX: StataCorp LP). A
203 significance level of $p < 0.05$ was considered statistically significant, indicating the
204 presence of significant differences between the groups.

205 *Ethical issues*

206 The study protocol (CEISH 659-2022) received ethical approval from the Ethics
207 Committee for Research in Human Beings of the Pontifical Catholic University of
208 Ecuador, following an expedited review process.

209 **Results**

210 Descriptive results from the total sample are shown in **Table 1**. In this study
211 population of $n=9286$, most participants were female (74.65%). The mean age of
212 the population was 51.58 years (± 23.00), and the age range varied from 1-2 years
213 to 100-130 years. The mean concentration of 25-hydroxyvitamin D (25(OH)D) was
214 27.53 ng/mL (± 14.11). Regarding 25-hydroxyvitamin D (25(OH)D) levels, 64.58%
215 of the participants had inadequate levels, defined as a concentration of 25-
216 hydroxyvitamin D (25(OH)D) below 20 ng/mL. In addition, suggestive toxicity,
217 indicating potential harm due to excess 25-hydroxyvitamin D (25(OH)D), was
218 present in 0.62% of the population, with a 25(OH)D concentration limit greater than
219 100 ng/mL. There was missing information because some participants did not
220 provide their sex. The presented means and standard deviations provide more
221 information about the age distribution and 25-hydroxyvitamin D (25(OH)D)
222 concentration within the study population.

223 **Table 1: Demographics, 25-hydroxyvitamin D (25(OH)D) Levels, and Inadequate and**
224 **Suggestive Toxicity of 25-hydroxyvitamin D (25(OH)D) of the Study Population**
225 **(N=9286)**

Variable	Statistics
Sex	
Female, n (%)	6932 (74.65%)
Male, n (%)	2318 (24.96%)
Not registered, n (%)	36 (0.39%)
Mean Age (\pm SD)	51.58 years (\pm 23.00)
Age Range (Years)	
1-2, n (%)	34 (0.37%)
3-5, n (%)	93 (1.01%)
6-11, n (%)	275 (2.98%)
12-17, n (%)	440 (4.76%)
18-65, n (%)	5630 (60.92%)
66-79, n (%)	1685 (18.23%)
80-99, n (%)	1070 (11.58%)
100-130, n (%)	14 (0.15%)
Mean 25-hydroxyvitamin D (25(OH)D) Concentration (\pm SD)	27.53 ng/mL (\pm 14.11)
Inadequate 25-hydroxyvitamin D (25(OH)D) Level	
Yes, n (%)	5997 (64.58%)
Suggestive Toxicity	
Yes, n (%)	58 (0.62%)
<i>Notes:</i>	
1. <i>Inadequate 25-hydroxyvitamin D (25(OH)D) Level</i> was defined as having a concentration of 25-hydroxyvitamin D (25(OH)D) less than 20 ng/mL.	
2. <i>Suggestive Toxicity</i> was defined based on the presence of symptoms indicating potential harm or risk due to excess 25-hydroxyvitamin D (25(OH)D), as ascertained by medical evaluation, and when the concentration of 25-hydroxyvitamin D (25(OH)D) exceeded 100 ng/mL.	
3. Participants who did not disclose their gender are listed as 'Not Disclosed' under the 'Sex' category.	
4. Age is categorized into ranges for easier data interpretation.	
5. The means for age and 25-hydroxyvitamin D (25(OH)D) concentration are presented with their respective standard deviations.	

226


227 Additionally, regarding the two secondary analyses, First, in the subsample
 228 analysis, no significant differences were found in inadequate 25-hydroxyvitamin D

229 (25(OH)D) levels between those without self-reported diseases (63%), those
230 without any medication (64%), those with any self-reported disease (64%), and
231 those taking any medication (61%) (**S1 Table**). Inadequate levels were considered
232 based on specific criteria related to Vitamin D status. These findings suggest that
233 the results of our study are more generalizable to the general population from
234 which the sample was drawn, since there does not seem to be a selection bias
235 related to the presence of diseases. Furthermore, when comparing 25-
236 hydroxyvitamin D (25(OH)D) levels between cities located at different altitudes:
237 Among the participants from Quito, Ambato and Ibarra, 64.18% had inadequate
238 levels, while 52.74% of the participants from Santo Domingo had inadequate levels
239 (chi-square = 18.1854, $p < 0.001$). These findings suggest that altitude may play a
240 role in 25-hydroxyvitamin D (25(OH)D) status, as people residing at higher
241 altitudes are more likely to have inadequate levels.

242 Regarding the evolution of concentration of 25-hydroxyvitamin D (25(OH)D) across
243 years, (**S2Table**) provides an overview of 25-hydroxyvitamin D (25(OH)D) levels,
244 suggestive toxicity, and inadequate levels in different years and age groups. In
245 2018, a significant difference in the prevalence of deficiency was observed
246 between age groups, with the highest proportion in children and adolescents
247 (42.9%), followed by young adults (43.0%), middle-aged adults (20.4%) and older
248 adults (33.0%). Similarly, in 2021 a significant difference was found, with the
249 highest proportion of deficiency in children and adolescents (29.1%), followed by
250 older adults (26.1%), young adults (28.0%) and middle-aged adults (21.6%).
251 Regarding inadequate levels, the prevalence varied between years and age
252 groups, with the highest figures being observed in 2021 (2,695) and in the group of
253 middle-aged adults (1,099). Suggestive toxicity was identified in a small number of
254 cases, mainly in older adults. In general, there was a significant association
255 between the year and the prevalence of deficiency and inadequate levels of 25-
256 hydroxyvitamin D (25(OH)D), indicating variations over time.

257 We can observe the trend of monthly average plasma of 25-hydroxyvitamin D
258 (25OHD) concentration during the pre-pandemic and pandemic periods. During the

259 pandemic period, although the values of 25-hydroxyvitamin D (25OHD) remain
260 inadequate, there is an evident increase in the monthly average concentration of
261 25-hydroxyvitamin D (25OHD). It increases from 2.4 ng/mL in 2018 to 2022 (Figure
262 1).



263

264 **Figure 1. Monthly mean 25-hydroxyvitamin D (25OHD) concentration pre-pandemic**
265 **and pandemic period.**

266 The results of the regression analysis (**Table 2**) revealed that there was a
267 statistically significant average monthly increase in 25-hydroxyvitamin D (25(OH)D)
268 concentration of 0.133 units ($p=0.006$). The period after March 2020, compared
269 with the period before March 2020, was associated with a non-significant reduction
270 in mean 25-hydroxyvitamin D (25(OH)D) concentration of 1.605 units ($p=0.477$).
271 However, the interaction between the period after March 2020 and time was not
272 significant ($p=0.909$), suggesting that there was no additional monthly change in
273 25-hydroxyvitamin D (25(OH)D) concentration after March 2020 beyond the
274 increase. overall monthly. The constant term indicated a significant baseline mean
275 25-hydroxyvitamin D (25(OH)D) concentration of 24.004 units at the start of the

276 study ($p < 0.001$). The general model explained approximately 40.28% of the
 277 variation in the average monthly concentration of 25-hydroxyvitamin D (25(OH)D)
 278 (R-squared=0.4028, R-squared=0.3629) and was statistically significant ($F=10.12$,
 279 $p < 0.001$).

280 **Table 2: Regression analysis of monthly average 25-hydroxyvitamin D (25(OH)D) concentration,**
 281 **before and after March 2020.**

Variable	Coefficient		
	(Average Monthly 25-hydroxyvitamin D (25(OH)D) concentration)	t statistic	p-value
Time* (per each month)	0.133	2.90	0.006
Post-March 2020** (1)	-1.605	-0.72	0.477
Post-March 2020*Time***	0.008	0.11	0.909
Constant****	24.004	33.94	<0.001

* The "Time" coefficient refers to the average monthly increase in 25-hydroxyvitamin D (25(OH)D) concentration across all participants in the study.
 ** "Post-March 2020 (1)" is the average difference in 25-hydroxyvitamin D (25(OH)D) concentration for all months after March 2020 (the 27th month of the study), compared to the months before March 2020.
 *** "Post-March 2020*Time" is the interaction term, representing any additional monthly change in Vitamin D concentration after March 2020, beyond the general monthly increase.
 ****The Constant term represents the average 25-hydroxyvitamin D (25(OH)D) concentration at the start of the study (Time = 0).

282

283 The proportion of toxicity across 2018 to 2021 increased significantly and the
 284 inadequate levels of 25-hydroxyvitamin D (25(OH)D) reduces in the same period,
 285 but with a non-significant change (**S3, S4 Tables**). These findings highlight the
 286 presence of a general upward trend in 25-hydroxyvitamin D (25(OH)D)
 287 concentration over time, but no additional significant monthly change after the
 288 onset of the COVID-19 pandemic in March 2020. Results from the regression
 289 model Poisson tests indicate a significant increase in the prevalence of toxicity
 290 (**Table 3**) during the period from 2018 to 2021. Specifically, the prevalence of

291 toxicity was found to be 6.53 times higher in 2020 and 7.37 times higher in 2021
292 compared to the base year 2018. In contrast, the prevalence of inadequate 25-
293 hydroxyvitamin D (25(OH)D) levels (**Table 4**) showed a slight but not statistically
294 significant decrease over the same period. The prevalence was found to be 3.5%
295 lower in 2020 and 8% lower in 2021 compared to 2018. These findings suggest
296 divergent trends in the two health outcomes over the study period.

297 **Table 3: Poisson Regression Results for Toxicity* (2019-2021)**

Year	Coefficient	Standard Error	z-statistic	P-value	Prevalence Ratio
2019	-0.5614968	1.414.213	-0.40	0.691	0.57
2020	1.876.703	1.027.402	1.83	0.068	6.53
2021**	1.997.484	1.013.072	1.97	0.049	7.37

*Suggestive Toxicity was defined based on the presence of symptoms indicating potential harm or risk due to excess 25-hydroxyvitamin D (25(OH)D), as ascertained by medical evaluation, and when the concentration of 25-hydroxyvitamin D (25(OH)D) exceeded 100 ng/mL.

**The positive coefficient suggests a positive relationship between the year 2021 and toxicity, the p-value < 0.05, indicating statistical significance.

298

299 **Table 4: Poisson Regression Results for Inadequate Vitamin D Level* (2019-2021)**

Year	Coefficient	Standard Error	z-statistic	P-value	Prevalence Ratio
2019**	0.0111135	0.0524749	0.21	0.832	1.01
2020**	-0.0359239	0.0492221	-0.73	0.465	0.965
2021**	-0.0830686	0.0461695	-1.80	0.072	0.92

* Inadequate 25-hydroxyvitamin D (25(OH)D) Level was defined as having a concentration of 25-hydroxyvitamin D (25(OH)D) less than 20 ng/mL.

** These results suggest that there is no strong and consistent evidence for significant changes in the prevalence of inadequate vitamin D levels across the years 2019, 2020, and 2021.

300

301 Discussion

302 Main findings

303 This study revealed a high prevalence of inadequate levels of 25-hydroxyvitamin D
304 (25(OH)D) (64.58%) among individuals attending a private laboratory in Quito,

305 Ecuador. These findings align with a meta-analysis conducted between 2000 and
306 2022, which estimated the global and regional prevalence of deficiency in serum
307 25-hydroxyvitamin D levels. The meta-analysis included 308 studies with
308 7,947,359 participants from 81 countries, finding that 15.7% had levels below 12
309 ng/dL and 47.9% had levels below 20 ng/dL. Although the prevalence slightly
310 decreased from 2000–2010 to 2011–2022, it remained at a high level[10].
311 Similarly, another meta-analysis conducted in an Asian population, including
312 746,564 subjects, reported that 22.82% had levels below 12 ng/dL and 57.69%
313 had levels below 20 ng/dL, indicating a high prevalence of 25-hydroxyvitamin D
314 (25(OH)D) deficiency in Asia. 25-hydroxyvitamin D (25(OH)D) levels varied based
315 on gender, age group, region, altitude, and disease. Several factors contributed to
316 these results, including dietary habits. Vitamin D is only present in a few foods,
317 such as fish liver oil and fatty fish, which are not commonly consumed by Asians,
318 especially central Asians. Additionally, Asians tend to prefer a lighter skin color,
319 leading to the use of sunscreen and parasols outdoors, which reduces the
320 penetration of ultraviolet B (UVB) and subsequently decreases vitamin D synthesis.
321 Clothing habits also play a significant role, as many individuals in western and
322 southern Asia, where Muslim populations reside, wear long robes and veils that
323 cover the skin. Moreover, people living in southern and Southeast Asia generally
324 have darker skin, which can block UVB penetration. Economic development also
325 influences vitamin D levels, particularly in Asian countries that are still developing
326 and lack access to effective vitamin D supplements[10].

327 Furthermore, another meta-analysis estimated the prevalence of 25-
328 hydroxyvitamin D (25(OH)D) deficiency in Africa. This analysis included 119
329 studies with 21,474 participants from 23 countries. The findings indicated that
330 18.46% had values below 12 ng/dL and 34.22% had values below 20 ng/dL. The
331 prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency exhibited regional
332 variation, with the highest rates observed in northern African countries and South
333 Africa[11]. Among population subgroups, women, newborn babies, and urban
334 populations had the lowest concentrations of 25(OH)D. Notably, populations living
335 in urban areas exhibited lower 25(OH)D concentrations compared to rural

336 populations, potentially due to limited sunlight exposure duration or reduced dietary
337 intake of vitamin D. Conversely, the populations in Africa that practiced traditional
338 lifestyles, including nomadic animal rearing, hunting, and gathering, demonstrated
339 the highest 25(OH)D concentrations[11].

340 In a meta-analysis that estimated the prevalence of 25-hydroxyvitamin D
341 (25(OH)D) deficiency in South America, 96 studies with a total of 227,758
342 participants were included from an initial pool of 9,460 articles. The overall
343 prevalence of 25-hydroxyvitamin D (25(OH)D) deficiency, defined by a 25(OH)D
344 concentration below 20 ng/mL, was found to be 34.76%. Lifestyle factors such as
345 spending more time indoors for work, leisure, and physical activities, coupled with
346 dietary patterns and public health campaigns that promote sunlight avoidance and
347 skin protection, likely contribute to the lower-than-expected concentrations of
348 25(OH)D in this region[5].

349 Ecuador, situated in the tropical zone, is longitudinally crossed by the Andes
350 mountain range, which imparts distinct and prominent topographical characteristics
351 throughout the country. The altitude of Ecuador's regions holds significant influence
352 over various health outcomes experienced by its population[12]. Within the scope
353 of this study, a pronounced disparity in inadequate 25-hydroxyvitamin D (25(OH)D)
354 levels was observed in laboratory results obtained from individuals residing in
355 Quito, positioned at an approximate elevation of 2,850 meters above sea level, in
356 comparison to samples collected from individuals in Santo Domingo, situated at a
357 lower altitude of approximately 625 meters above sea level. Upon comparing
358 participants from Quito, Ambato, and Ibarra with those from Santo Domingo, it was
359 found that 64.18% of individuals from higher-altitude cities exhibited inadequate
360 25-hydroxyvitamin D (25(OH)D) levels, whereas the percentage was 52.74%
361 among those from Santo Domingo. These findings indicate a potential correlation
362 between altitude and 25-hydroxyvitamin D (25(OH)D) status, suggesting that
363 individuals inhabiting higher altitudes are more susceptible to insufficient levels of
364 this nutrient. Therefore, it is crucial to consider regional factors when evaluating 25-
365 hydroxyvitamin D (25(OH)D) status and devising appropriate interventions. These

366 results align with other studies, including research conducted in Asia by Zhiwei
367 Jiang, which revealed that individuals residing at lower altitudes (≤ 500 m) tend to
368 exhibit higher 25-hydroxyvitamin D (25(OH)D) levels compared to those at higher
369 altitudes (> 500 m)[10]. Furthermore, it has been observed that people living in
370 high-altitude regions often encounter difficulties in accessing effective vitamin D
371 supplements[10]. The studies conducted in South America have incorporated two
372 fundamental factors, namely altitude and diet, into their analyses. At higher
373 altitudes, the atmosphere is thinner, resulting in reduced absorption of ultraviolet
374 radiation (UV levels increase by 10% to 12% with each 1000-meter increase in
375 altitude)[5].

376 The findings of this study revealed a significant prevalence of inadequate 25-
377 hydroxyvitamin D (25(OH)D) levels in the population, while the incidence of 25-
378 hydroxyvitamin D (25(OH)D) toxicity was relatively low (0.62%). Interestingly,
379 divergent changes were observed in these indicators during the study period.
380 Although inadequate levels showed a non-significant reduction, there was a
381 notable increase in the prevalence of toxicity from 2018 to 2021. These results
382 underscore a concerning trend in the 25-hydroxyvitamin D (25(OH)D) status of the
383 population. These findings are consistent with a study conducted in Ireland that
384 aimed to investigate the impact of the COVID-19 pandemic on vitamin D status and
385 the usage of newly introduced vitamin D supplements. A trend analysis based on
386 laboratory data revealed a threefold rise in the yearly average of 25(OH)D during
387 the initial year of the pandemic, compared to previous analyses. This trend
388 suggests potential benefits for individuals with low vitamin D status but also
389 highlights the risk for those with already high levels, especially considering the
390 increasing availability of high-dose supplements[6].

391 The increased consumption of vitamin D supplements by the general population,
392 including therapeutic and high-dose formulations, without adequate medical
393 supervision, can significantly elevate the risk of exogenous hypervitaminosis D,
394 commonly known as vitamin D toxicity. This condition can manifest symptoms of
395 hypercalcemia[13]. Therefore, it is essential to ensure that the intake of vitamin D

396 is monitored by healthcare professionals to prevent overdosing and the associated
397 severe health consequences[3,14,15].

398 Excessive intake of vitamin D can lead to the accumulation of the nutrient in the
399 body for extended periods, up to 18 months, resulting in chronic toxic effects such
400 as nephrocalcinosis, hypercalcemia, and hypercalciuria. In the past, fortification of
401 foods, such as milk, was recommended as a public health strategy to prevent
402 vitamin D deficiency and low 25-hydroxyvitamin D (25(OH)D) status. However,
403 cases of increased hypercalcemia associated with excessive intake of fortified
404 foods have been reported[3,14,15].

405 During the pandemic, there was a notable interest in studying the relationship
406 between 25-hydroxyvitamin D (25(OH)D) levels and COVID-19. A study aimed at
407 identifying if online search interest in vitamin D increased with the pandemic
408 burden and analyzing the accuracy of public health messaging regarding vitamin D
409 in online news articles found that a significant number of articles provided
410 conflicting information or incorrectly advised suprathreshold doses. This study
411 emphasizes the opportunity for public health organizations to capitalize on the
412 increased interest in vitamin D during the pandemic and disseminate accurate
413 information to raise awareness[16].

414 However, it is important to acknowledge the limitations of this study. Important
415 factors such as skin pigmentation, socioeconomic conditions, diet, sun exposure
416 habits, cultural practices, and skin coverage with clothing were not considered in
417 the analysis. These factors can influence 25-hydroxyvitamin D (25(OH)D) levels
418 and should be considered in future research.

419 The results of this study reveal a high prevalence of 25-hydroxyvitamin D
420 (25(OH)D) deficiency, indicating the need for strategies to prevent deficiency.
421 However, the increase in toxicity also raises concerns and highlights the
422 importance of rational prescribing of vitamin D supplements and educating the
423 population to avoid self-medication. To optimize resource allocation and prioritize
424 those at higher risk, it may be beneficial to focus vitamin D testing on specific

425 populations. Individuals with malabsorption syndromes, individuals undergoing
426 steroid therapy, or older adults who are confined to their homes are examples of
427 higher-risk groups. Assessing serum of 25-hydroxyvitamin D (25(OH)D) levels in
428 these cases can provide valuable clinical insights and inform appropriate
429 interventions.

430 **Supporting Information**

431 ***S1 Table: Prevalence of inadequate levels of Vitamin D among: (i) those who does not have self-***
432 ***reported diseases, (ii) those who are not taking medications, (iii) those who have reported any***
433 ***chronic disease, and (iv) those who are taking any medication.***

Variable	n=919
No self-reported diseases, <i>n (%)</i>	399 (63)
No medications, <i>n (%)</i>	471 (64)
Any self-reported disease, <i>n (%)</i>	181 (64)
Any medication, <i>n (%)</i>	109 (61)
Inadequate levels were defined as a 25-hydroxyvitamin D (25(OH)D) concentration below 20 ng/mL.	

434 **S2 Table: 25-hydroxyvitamin D (25(OH)D) levels, suggestive toxicity, and inadequate levels per year and age group.**

Year	25-hydroxyvitamin D (25(OH)D)	Age ranges							
		1-2 (n=34)	3-5 (n=93)	6-11 (n=275)	12-17 (n=440)	18-65 (n=5630)	66-79 (n=1685)	80-99 (n=1070)	>99 (n=14)
2018	Mean concentration in ng/mL, mean (SD)	-	19.4 (8.0)	24.1 (17.0)	21.8 (10.9)	26.4 (12.0)	26.6 (10.4)	22.3 (9.6)	12.2 (4.6)
	Inadequate levels, <i>n (%)</i> *	-	11 (58)	27 (44)	38 (45)	311 (72)	93 (69)	78 (85)	3 (100)
	Suggestive of toxicity, <i>n (%)</i> **	-	-	1 (2)	-	-	-	-	-
2019	Mean concentration in ng/mL, mean (SD)	-	30.5 (10.7)	28.4 (6.9)	27.7 (10.7)	26.3 (10.8)	25.9 (11.0)	24.3 (12.6)	-
	Inadequate levels, <i>n (%)</i> *	-	9 (39)	2 (5)	11 (19.7)	677 (71.9)	206 (76.0)	96 (76.8)	-
	Suggestive of toxicity, <i>n (%)</i> **	-	-	-	-	1 (0.1)	-	-	-
2020	Mean concentration in ng/mL, mean (SD)	23.8 (13.4)	30.2 (16.3)	29.5 (15.3)	22.9 (8.6)	27.5 (14.4)	30.1 (17.6)	24.2 (16.7)	8 (-)
	Inadequate levels, <i>n (%)</i> *	4 (50)	2 (13)	11 (19)	34 (40)	989 (67)	255 (65)	202 (79)	2 (100)
	Suggestive of toxicity, <i>n (%)</i> **	-	-	1 (2)	-	10 (1)	4 (1)	3 (1)	-
2021	Mean concentration in ng/mL, mean (SD)	30.6 (12.6)	32.6 (10.2)	27.2 (11.0)	23.6 (10.9)	29.1 (14.7)	29.7 (16.2)	24.8 (15.5)	17.0 (12.6)
	Inadequate levels, <i>n (%)</i> *	5 (20)	-	25 (23)	79 (39)	1646 (65)	500 (62)	427 (77)	8 (89)
	Suggestive of toxicity**	-	-	-	1 (1)	21 (1)	10 (1)	6 (1)	-
2022	Mean concentration in ng/mL, mean (SD)	21.7 (-)	17.2 (10.6)	24.1 (6.4)	20.7 (6.8)	30.1 (11.6)	29.4 (9.8)	27.3 (15.7)	-
	Inadequate levels, <i>n (%)</i> *	-	1 (50)	3 (27.2)	4 (40)	138 (58)	45 (62)	26 (60)	-
	Suggestive of toxicity, <i>n (%)</i> **	-	-	-	-	-	-	-	-

* Inadequate levels" when the values were; for children <20 ng/ml; for young adults <30 ng/ml; for pregnant women <20 ng/ml; and, for elderly people <30 ng/ml
 ** 'Suggestive of toxicity' of vitamin D are not represented in this table. Toxicity generally occurs at 25(OH)D concentrations greater than 100 ng/ml.

435 **S3 Table: Annual Prevalence Rates of Vitamin D Toxicity (%).**

Year	n	Prevalence Rate (%)	95% Confidence Interval
2018	835	0.12	0.02 - 0.85
2019	1464	0.07	0.01 - 0.48
2020	2301	0.78	0.49 - 1.24
2021	4305	0.88	0.64 - 1.21

Toxicity generally occurs at 25(OH)D concentrations greater than 100 ng/ml.

436

437 **S4 Table: Proportion of patients with inadequate vitamin D levels per year**

Año	n	Proporción	Intervalo de confianza del 95%
2018	835	0.68	0.65 - 0.71
2019	1464	0.69	0.66 - 0.71
2020	2301	0.66	0.64 - 0.68
2021	4305	0.63	0.61 - 0.64

Less than 20 ng/ml for general population and less than 30 ng/ml for older adults and pregnant women

438

439 **Footnotes:**

440 **Acknowledgment:** The authors express their sincere appreciation to the
441 healthcare professionals at Zurita & Zurita Laboratories for their expert handling of
442 the samples, which significantly contributed to the accuracy of our study.
443 Furthermore, ChatGPT from OpenAI was utilized to improve the document's overall
444 writing quality. No AI was involved in the study design, data analysis, interpretation
445 or substantial writing and reviewing of the manuscript.

446 **Funding statement:** This research received no specific grant from any funding
447 agency in the public, commercial or not-for-profit sectors.

448 **Author Contributions**

449 Conceptualization: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín

450 Data curation: Iván Dueñas-Espín, Betzabé Tello, Camilo Zurita-Salinas

451 Formal analysis: Iván Dueñas-Espín, Betzabé Tello, Camilo Zurita-Salinas

452 Investigation: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete
453 Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José
454 Pareja-Maldonado.

455 Methodology: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín

456 Validation: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-Espín, Jeannete
457 Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-Muñoz, José
458 Pareja-Maldonado.

459 Writing – original draft: Betzabé Tello, Iván Dueñas-Espín

460 Writing – review & editing: Camilo Zurita-Salinas, Betzabé Tello, Iván Dueñas-
461 Espín, Jeannete Zurita, William Acosta, Cristina Aguilera León, Andrés Andrade-
462 Muñoz , José Pareja-Maldonado.

463 Declaration of interest: None

464 **Patient consent for publication:** Not required.

465 **Data-sharing statement:** Data are available upon reasonable request. All data
466 relevant to the study were included in the article.

467 **Ethics approval:** The study protocol (CEISH 659-2022) received ethical approval
468 from the Ethics Committee for Research in Human Beings of the Pontifical Catholic
469 University of Ecuador, following an expedited review process.

470 **References**

471 1 Cashman KD. Vitamin D Deficiency: Defining, Prevalence, Causes, and
472 Strategies of Addressing. *Calcif. Tissue Int.* 2020;**106**:14–29.
473 doi:10.1007/s00223-019-00559-4

474 2 Melmed S, Auchus R, Goldfi A, *et al.* *Williams. Tratado de endocrinología.*
475 14.^a edici. España: 2021.

- 476 3 Gallagher JC, Rosen CJ. Vitamin D: 100 years of discoveries, yet
477 controversy continues. *lancet Diabetes Endocrinol* 2023;**11**:362–74.
478 doi:10.1016/S2213-8587(23)00060-8
- 479 4 Cui A, Zhang T, Xiao P, *et al.* Global and regional prevalence of vitamin D
480 deficiency in population-based studies from 2000 to 2022: A pooled analysis
481 of 7.9 million participants. *Front Nutr* 2023;**10**.
482 doi:10.3389/fnut.2023.1070808
- 483 5 Mendes M, Gomes A, Araújo M, *et al.* Prevalence of vitamin D deficiency in
484 South America: A systematic review and meta-analysis. *Nutr Rev* Published
485 Online First: 2023. doi:10.1093/nutrit/nuad010
- 486 6 Mckenna MJ, Lyons OC, Flynn MAT, *et al.* COVID-19 pandemic and vitamin
487 D: rising trends in status and in daily amounts of vitamin D provided by
488 supplements. *BMJ Open* 2022;**12**:1–8. doi:10.1136/bmjopen-2021-059477
- 489 7 Rustecka A, Maret J, Drab A, *et al.* The impact of covid-19 pandemic during
490 2020–2021 on the vitamin d serum levels in the paediatric population in
491 warsaw, poland. *Nutrients* 2021;**13**. doi:10.3390/nu13061990
- 492 8 Ruiz-garc A, Pallar V, Tur M, *et al.* Vitamin D Supplementation and Its Impact
493 on Mortality and Cardiovascular Outcomes: Systematic Review and.
494 2023;;1–16.
- 495 9 Berger MM, Shenkin A, Schweinlin A, *et al.* ESPEN micronutrient guideline.
496 *Clin Nutr* 2022;**41**:1357–424. doi:10.1016/j.clnu.2022.02.015
- 497 10 Cui X, Zhai Y, Wang S, *et al.* Effect of the COVID-19 Pandemic on Serum
498 Vitamin D Levels in People under Age 18 Years: A Systematic Review and
499 Meta-Analysis. *Med Sci Monit* 2022;**28**:1–9. doi:10.12659/MSM.935823
- 500 11 Mogire RM, Mutua A, Kimita W, *et al.* Prevalence of vitamin D deficiency in
501 Africa: a systematic review and meta-analysis. *Lancet Glob Heal*
502 2020;**8**:e134–42. doi:10.1016/S2214-109X(19)30457-7

- 503 12 Robles Rodríguez JB, Pazmiño K, Jaramillo A, *et al.* Relación entre
504 deficiencia de vitamina D con el estado nutricional y otros factores en
505 adultos de la región interandina del Ecuador. *Perspect en Nutr Humana*
506 2022;**24**:35–48. doi:10.17533/udea.penh.v24n1a03
- 507 13 Muneer S, Siddiqui I, Majid H, *et al.* Practices of vitamin D supplementation
508 leading to vitamin D toxicity: Experience from a Low-Middle Income Country.
509 *Ann Med Surg* 2022;**73**:103227. doi:10.1016/j.amsu.2021.103227
- 510 14 Amrein K, Scherkl M, Hoffmann M, *et al.* Vitamin D deficiency 2.0: an update
511 on the current status worldwide. *Eur J Clin Nutr* 2020;**74**:1498–513.
512 doi:10.1038/s41430-020-0558-y
- 513 15 Marcinowska-Suchowierska E, Kupisz-Urbanska M, Lukaszkiwicz J, *et al.*
514 Vitamin D Toxicity a clinical perspective. *Front Endocrinol (Lausanne)*
515 2018;**9**:1–7. doi:10.3389/fendo.2018.00550
- 516 16 Heer RS, Sandhu P, Wenban C, *et al.* Vitamin D in the news: A call for clear
517 public health messaging during Covid-19. *Nutr Health* 2022;**28**:733–9.
518 doi:10.1177/02601060221090293
- 519